Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma kallikrein (Homo sapiens (Human)) | BDBM416789 (1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416789 (1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416789 (1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416789 (1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
TBA | Citation and Details BindingDB Entry DOI: 10.7270/Q2J1078D | ||||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416789 (1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s... | Citation and Details BindingDB Entry DOI: 10.7270/Q2ZC862H | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416789 (1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
TBA | Citation and Details BindingDB Entry DOI: 10.7270/Q2XW4PXV | ||||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416789 (1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2HM5CNF | |||||||||||
More data for this Ligand-Target Pair |